The Cancer Dictionary

Total Page:16

File Type:pdf, Size:1020Kb

The Cancer Dictionary THE CANCER DICTIONARY Third Edition Michael J. Sarg, M.D. Associate Chief of Medical Oncology, St. Vincent’s Hospital, New York City Member of the teaching faculty of the St. Vincent’s Hospital Comprehensive Cancer Center Associate Professor of Clinical Medicine, New York Medical College Ann D. Gross, M.A., Gerontology Medical Writer A. D. Gross & Company, New York The Cancer Dictionary, Third Edition Copyright © 2000 and 1992 by Roberta Altman and Michael J. Sarg, M.D. Copyright © 2007 by Michael J. Sarg All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval systems, without permission in writing from the publisher. For information contact: Facts On File, Inc. An imprint of Infobase Publishing 132 West 31st Street New York NY 10001 ISBN-10: 0-8160-6411-3 ISBN-13: 978-0-8160-6411-3 Gross, Ann D. The cancer dictionary / Ann D. Gross, Michael J. Sarg.—Third. ed. p. cm. Includes bibliographical references and index. ISBN 0-8160-6411-3 (alk. paper) 1. Cancer—Dictionaries. I. Sarg, Michael. II. Title. RC262.A39 1999 616.99/4003 22—DC21 99-21201 Facts On File books are available at special discounts when purchased in bulk quantities for businesses, associations, institutions or sales promotions. Please call our Special Sales Department in New York at (212) 967-8800 or (800) 322-8755. You can find Facts On File on the World Wide Web at http://www.factsonfile.com Text design by Cathy Rincon Cover design by Salvatore Luongo Illustrations on pages 43–46, 66, 111, and 183 by Jeremy Eagle Illustrations on pages 38 and 164 by Sholto Ainslie Printed in the United States of America VB Hermitage 10 9 8 7 6 5 4 3 2 1 This book is printed on acid-free paper. This third edition of The Cancer Dictionary is dedicated to the fond memory of Roberta Altman, who left us in 2001, overtaken by a major recurrence of her breast cancer. To the final days she was passionate about living and about her cause to educate people on resisting and doing battle with a disease she fought with courage and with a determination to strengthen others by providing them with in-depth information. CONTENTS Acknowledgments vii Introduction to the Third Edition ix Introduction to the Previous Edition xi Introduction to the First Edition xiii How to Use This Book xv The Cancer Dictionary 1 Appendix I: Noteworthy Web Sites of National Organizations for Cancer and AIDS 343 Appendix II: Comprehensive Cancer Centers by State 358 Appendix III: Clinical Cancer Centers by State 363 Subject Index 366 Bibliography 387 Index 391 ACKNOWLEDGMENTS Ongoing thanks to Laurie Likoff at Facts On File for her understanding of the pressing need to update this Cancer Dictionary; she continues to show a com- mitment that carries the project. Thanks also to agent Joe Vallely and to Janis Vallely for their encouragement and help. Our gratitude also goes out to the hundreds of organizations dedicated to the palliation and cure of cancer and related diseases and the remarkable resources they have put into creating Web sites that are comprehensive, interactive, invaluable tools for researchers, patients, and practitioners alike. And thanks, too, to our spouses, and to Natalie Berger, who understood that work on this third edition would be a long project requiring many hours of excused absences at events and encouraged us to persevere and complete this book in the most thorough way that would be a true service to our readers. vii INTRODUCTION TO THE THIRD EDITION There is no question that the pursuit of a cure for cancers of many organs—including breast, prostate, cancer—or at least the means of turning it into a and lung cancer, as well as some of the leukemias— chronic disease we can live with for decades—con- burst onto the scene. In this, the third edition, my tinues to be a national priority. The National coauthor, Ann Gross, and I found ourselves writing Cancer Institute estimated that it would spend and making entries almost up to the moment when some $4.9 billion in fiscal year 2005, in addition to the book had to go to print. Each time we reviewed all the money that private industry and other state the material, theoretically for a “last glance,” we and federal agencies spent in search of the means to found we were e-mailing and faxing each other the vanquish an enemy that still manages to exact its latest articles in the treatment of so many different toll on too many of all ages. In fact, since the publi- cancers, including cancers of the breast, lung, and, cation of the last edition, Roberta Altman, who was most recently, in January 2006, ovarian cancer. And the primary force in creating the prior editions of with each new FDA approval, we both felt strongly this book, succumbed to her long battle with breast that we could not let the book be issued without cancer. adding “just this one new drug.” However, the world of cancer care and therapy As such, I am happy to report that you will find continues to progress at lightning speed. No sooner in this third edition entries for more theapeutic did we publish the revised edition of The Cancer modalities than ever before. Dictionary than advances in the management of — Michael J. Sarg, M.D. ix INTRODUCTION TO THE PREVIOUS EDITION The last five years have seen an explosion of new Over the past years, there has been a rebirth of concepts in basic molecular biology and technol- interest in medical ethics, stimulated by major ogy that have been widely discussed and dissemi- trends in health care, including awareness of eco- nated by the media. Many of these new develop- nomic concerns, issues of access to competent care ments in understanding have led to practical for all Americans, and multiple issues concerning applications—new drugs, new treatments and end-of-life care. At medical schools, more attention treatment strategies, etc. All of this has been ampli- is being given to integrating courses in humanism fied and dispersed by the growth of the World and medical ethics into the already crowded cur- Wide Web. riculum to help future physicians and other health- Many patients, as well as their friends and rela- care workers properly frame these difficult ques- tives, use the Internet to search for the very latest tions. information and treatment options. However, for Among workers in the field of cancer care, there many the plethora of previously inaccessible infor- is evident a real sense of optimism related to the mation has created even greater confusion, fre- application of state-of-the-art care as well as to new quently making it difficult to resolve the issues of prevention strategies. The tide in the “war on can- choice. Information, while often invaluable, is not cer” may finally be turning. of itself a treatment for a serious illness. — Michael J. Sarg, M.D. xi INTRODUCTION TO THE FIRST EDITION CANCER! more interested than ever before in good health in general and in cancer in particular. There is still Few other words in our common experience are so fear; there is still dread; and there is still a great feared, dreaded, and charged with emotion. amount of emotion surrounding cancer. But there Growing up in the late forties, I can recall my fam- is also encouragement, hope, and optimism. ily whispering about the disease, to avoid using the Cancer has come out of the closet. Hardly a day word. They referred to “it” in hushed tones with goes by that there isn’t some report on television, on looks of dismay. To me, those afflicted with it the radio, and in all the newspapers on the progress seemed doomed, the ultimate unfortunate ones. that is being made—the newest drug for cancer Their illness was itself unspeakable, treatment was treatment; the newest way to detect it; what one can “mysterious” and thought to be ineffective, and do to prevent it; and the newest way to “cure” can- their future was to confront unspeakable horror cer. The media are full of articles; talk show hosts until they finally died. If they didn’t die, they would openly discuss with their guests the battle they be disfigured—unable to live any kind of normal fought with cancer. While much of this may be life. They were “better off dead.” attributed to our obsession with “news,” there is no For many, the cause of such monumental mis- doubt that there is an ever-increasing abundance of fortunes, such as cancer, was based on religious information on cancer that is truly newsworthy. beliefs. “Bad” people got cancer. And of course if The mass media exposure of cancer has resulted you “got” cancer, your morality was questioned. in a more informed public and has played a role in Although there are still some people who believe dispelling some of the cancer myths. In the past, this, the number (fortunately) is dwindling. many people would wait before consulting a doc- Many of the old cancer myths—cancer is a tor. Their thinking was, “If I’ve got ‘it,’ there’s noth- death sentence; cancer is contagious; cancer only ing that can be done anyway; I’m just going to die.” happens to “bad” people—have been dispelled in And they would die, because the more advanced the face of tremendous advances in communication any cancer is when it’s diagnosed, the less likely it and technology.
Recommended publications
  • Master Agreement
    MASTER AGREEMENT Between The Medical Society of Prince Edward Island And The Government of Prince Edward Island And Health PEI April 1, 2015 - March 31, 2019 MASTER AGREEMENT TABLE OF CONTENTS SECTION A - GENERAL Article A1. Purpose of Agreement .......................................................................................1 Article A2. Application, Duration and Amendments ..........................................................1 Article A3. Interpretation and Definitions ...........................................................................1 Article A4. Recognition .......................................................................................................3 Article A5. Administrative Authority ..................................................................................4 Article A6. Information .......................................................................................................4 Article A7. Correspondence.................................................................................................5 Article A8. Negotiations ......................................................................................................5 Article A9. General Grievance Procedure ...........................................................................6 Article A10. Mediation ..........................................................................................................7 Article A11. Interest Arbitration ............................................................................................8
    [Show full text]
  • S.P. Strijk Stellingen
    INIS-mf —11067 y i; ••Ht g S.P. STRIJK STELLINGEN 1. Het verschil in diagnostische nauwkeurigheid tussen CT en lymfografie bij patiënten met maligne lymfoom berust voornamelijk op een verschil in sensitiviteit ten nadele van CT. 2. CT is geen alternatief voor stadiëringslaparotomie. 3. De informatie verkregen met behulp van CT en lymfo- grafie is voor 85% overlappend en voor 15% aanvullend. Tegenstrijdige informatie kan meestal afdoende ver- klaard worden. 4. Het routinematig verrichten van een CT van de thorax als onderdeel van het stadiëringsonderzoek bij patiën- ten met de ziekte van Hodgkin of non-Hodgkin lymfoom is niet zinvol. 5. De in-vivo bepaling van de miltgrootte met behulp van de CT-miltindexberekening kan aanwijzingen geven over eventuele lymfoomlocalisatie in de milt bij .patiënten met de ziekte van Hodgkin of non-Hodgkin lymfoom. 6. Het optreden van lymfklierverkalkingen bij de ziekte van Hodgkin is een prognostisch gunstig teken. 7. Het verrichten van een lymfografie na een abdominale CT-scan levert alleen additionele informatie op wanneer de CT géén of twijfelachtige afwijkingen laat zien. 8. Magnetic Resonance Imaging (MRI) is een gevoelige methode voor het opsporen van afwijkingen in het been- merg bij patienter, met leukemie, maligne lymfoom of metastasen. (DO Oison et al., Invest. Radiol. 1986; 21: 540-546). 9. Wanneer bij patiënten met een niet-seminomateuza testistumor wordt gekozen voor een zogenaamd "wait and see" beleid, dan dient bij screening op retroperitone- ale lymfkliermetastasen zowel een abdominale CT-scan als een lymfografie te worden verricht. 10. Bij de bepaling van de resectabiliteit van een pancreastumor kan een percutané transhepatische porto- grafie (PTP) bij een groot deel van de patiënten worden vermeden door het uitvoeren van een intra-arteriële digitale subtractie angiografie (i.a.
    [Show full text]
  • Iranian Journal of Nuclear Medicine
    IRANIAN JOURNAL OF NUCLEAR MEDICINE Iranian Journal of Nuclear Medicine is a peer-reviewed biannually journal of the Research Institute for Nuclear Medicine, Tehran University of Medical Sciences, covering basic and clinical nuclear medicine sciences and relevant application. The journal has been published in Persian (Farsi) from 1993 to 1994, in English and Persian with English abstract from 1994 to 2008 and only in English language form the early of 2008 two times a year. The journal has an international editorial board and accepts manuscripts from scholars working in different countries. Chairman & Chief Editor: Saghari, Mohsen; MD Associate Editor and Executive Manager: Beiki, Davood; PhD Scientific Affairs: Eftekhari, Mohammad; MD and Fard-Esfahani, Armaghan; MD Editorial Board Alavi, Abbas; MD (USA) Grammaticos, Philip C.; MD (Greece) Ay, Mohammad Reza; PhD (Iran) Mirzaei, Siroos; MD (Austria) Beheshti, Mohsen; MD (Austria) Najafi, Reza; PhD (Iran) Beiki, Davood; PhD (Iran) Rahmim, Arman; PhD (USA) Cohen, Philip; MD (Canada) Rajabi, Hossein; PhD (Iran) Dabiri-Oskooei, Shahram; MD (Iran) Saghari, Mohsen; MD (Iran) Eftekhari, Mohammad; MD (Iran) Sarkar, Saeed; PhD (Iran) Fard-Esfahani, Armaghan; MD (Iran) Zakavi, Seyed Rasoul; MD (Iran) ------------------------------------------------------------------------------------------------------- Editorial Office Iranian Journal of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, North Kargar Ave. 1411713135, Tehran, Iran Tel: ++98 21 88633333, 4 Fax: ++98 21 88026905 E-mail: [email protected] Website: http://irjnm.tums.ac.ir Indexed in/Abstracted by EMBASE, Scopus, ISC, DOAJ, Index Copernicus, EBSCO, IMEMR, SID, IranMedex, Magiran Vol 20 , Supplement 1 2012 INSTRUCTION TO AUTHORS Aims and Scope Review articles Iranian Journal of Nuclear Medicine is a peer-reviewed biannually These are, in general, invited papers, but unsolicited reviews, if of journal of the Research Institute for Nuclear Medicine, Tehran good quality, may be considered.
    [Show full text]
  • Snomed Ct Dicom Subset of January 2017 Release of Snomed Ct International Edition
    SNOMED CT DICOM SUBSET OF JANUARY 2017 RELEASE OF SNOMED CT INTERNATIONAL EDITION EXHIBIT A: SNOMED CT DICOM SUBSET VERSION 1.
    [Show full text]
  • RADIOLOGY HELP DOCUMENTS Procedures and Preps
    RADIOLOGY HELP DOCUMENTS Procedures and Preps YOUR HEALTH : OUR MISSION This document is designed to be a tool to assist you with Pre-Medication Guidelines for Contrast Allergies, Creatinine Requirements, Interventional Procedures and Biopsies, Clinical Indication Guidelines and Patient Preps. Scheduling Same day, outpatient exam: Contact Radiology at 605-882-7770 A future outpatient exam: Contact Central Scheduling at 605-882-7690 or 882-5438 or 882-5448 If a patient needs pre-medication for a previous contrast reaction you need to date and sign and obtain the pre-medication for the patient—the “Contrast Reaction Prophylaxis Suggestions for Premedication” *Fax requests for Oral Medications to the Campus Pharmacy at 605-882-7704, M-F 0830-1700, other hours to Main Pharmacy at 605-882-7694 *Fax Requests for Injectable Medications to Central Scheduling 605-882-6704 • Reports will still continue to come to the appropriate printers in all patient care areas • Reports can be accessed in CPSI, Chartlink, PACS and www.plhspacs.com • ER reports will be routed to the ED printer 1. Stat reports are 30 minutes or less 2. Inpatients and ASAP 4 hours or less 3. Routine outpatient reports are 24 hours from the time the exam is scheduled • Keep in mind, if an exam from any outside or attached clinic (Cardiology, Urology, Nephrology, Cancer Center, GLO, Dr. Jones, Brown Clinic, Sanford Clinic, Hanson/Moran Eye Clinic, Innovative Pain Clinic and VA Clinic) is ordered, the results will be available 24 hours from the time the exam is scheduled. If the patients follow up appointment to see the clinician and review the results is less than 24 hours from the time the exam is conducted, be sure to indicate this on the order so we can submit as an ASAP order.
    [Show full text]
  • 66 Lymphography in Malignant Histiocytosis
    66 Lymphology 9 (1976) 66-68 COipOJ © Georg Thieme Verlag Stuttgart withe (ECIL Lymphography in Malignant Histiocytosis: Case Report Lloyd R. Musumeci*, R.A. Castellino** an ear carryiJ •clinical Assistant, Department of Radiology, lstituto Nazinale Tumori, Milano; Professor ~ 20-3( of Radiology, University of Milano I develo • • John S. Guggenheim Fellow 1.g74-1975; Associate Professor of Radiology, Stanford toxici1 University Medical School, Stanford, Cattfornia; Visiting Professor of Radiology, lstituto after 1 Nazionale Tumori, Milano ly lO\\ cytes Summary to otll none, Malignant histiocytosis is an uncommon, progressive disease with a poor prognosis which is characterized by lymph malaise, fever, lymphadenopathy, and splenomegaly. Lymphadenopathy is commonly present at presentation negati" as well as during the course of the disease. The lymphographic findings in this case report were very similar to those encountered in malignant lymphoma, a not unexpected situation since the clinical and pathological Radia resemblances to histiocytic lymphoma are striking. and o: invest: Malignant histiocytosis is an uncommon disease which was described by Scott and Robb-8mith sensiti in 1939 as histiocytic medullary reticulosis (6). Since that time other cases have been added to on inc the literature variously called aleukemic reticulosis, histiocytic reticulosis, histiocytic leukemia, (Stem among others (1, 2). The term of malignant histiocytosis was introduced for this disease in Redd) 1966 by Rappaport (5), and should not be confused with the entity know as histiocytosis-X. group A comprehensive recent review of 29 cases by Warnke, Kim and Dorfman (7) details the clini­ irradi2 cal and pathologic features of this disease. 564 R a red\: Malignant histiocytosis affects ~ ages with no apparent predilection for any age group, although ed mi there may be a male predominance.
    [Show full text]
  • James Patient Education Handouts (A – Z)
    James Patient Education Handouts (A – Z) Click on the title to see the handout To narrow your search use “Ctrl + F” and enter a keyword Abdomen CT Scan - The James Abemaciclib Abiraterone (Zytiga) About Hospice Care About Your Visit at The James Gastrointestinal (GI) Clinic AC: Doxorubicin and Cyclophosphamide Acalabrutinib (Calquence) Acute Leukemia Ado-Trastuzumab Emtansine Advance Directives Afatinib (Gilotrif) Alectinib (Alecensa) After Your Breast Cancer Surgery After Your Spine or Joint Injection All About Me All About Me - Russian All About Me - Somali All About Me - Spanish Allogeneic Stem Cell Transplant Amyloidosis Clinic Physical Therapy Recommendations Anal Cancer Anastrozole (Arimidex) for Females Anastrozole (Arimidex) for Males Anticipatory Grief in Family/Caregivers Anticipatory Grief in Patients Antithymocyte Globulin (ATG) Apheresis Approaching the Final Days Areola Tattooing Aromatherapy Autologous Stem Cell Transplant Automated Whole Breast Ultrasound (ABUS) Avapritinib (Ayvakit) Axillary Web Syndrome Exercise Program Axitinib (Inlyta) Basics of Blood Sugars Basic Pilates Mat Routine BCG Therapy - Intravesical Treatment for Bladder Cancer Before Your Breast Cancer Surgery Benign Breast Surgery The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 9/15/2021 James Patient Education Handouts (A – Z) Click on the title to see the handout To narrow your search use “Ctrl + F” and enter a keyword Benign Pituitary Tumor Bevacizumab (Avastin) Bexarotene (Targretin) Bicalutamide (Casodex) Binimetinib (Mektovi) Bisphosphonates (taken by mouth) Bladder Cancer Internet Resources Bladder Irrigation Treatment for Bladder Cancer Blank Notes Page - The James Blood and Bone Marrow Question and Answer Sheet Blood and Marrow Transplant Blood Value Record Blood and Marrow Transplant Unit - B.M.T.U.
    [Show full text]
  • Artificial Neural Network Based Breast Cancer Screening: a Comprehensive Review
    1 Artificial Neural Network Based Breast Cancer Screening: A Comprehensive Review Subrato Bharati1, Prajoy Podder2, M. Rubaiyat Hossain Mondal3 Institute of Information and Communication Technology, Bangladesh University of Engineering and Technology Dhaka, Bangladesh [email protected],[email protected], [email protected] Abstract: Breast cancer is a common fatal disease for women. recognition than new testing methods [3, 4]. Some of the Early diagnosis and detection is necessary in order to improve well-known medical imaging systems for the diagnosis of the prognosis of breast cancer affected people. For predicting breast cancer are breast X-ray mammography, sonograms or breast cancer, several automated systems are already developed ultrasound imaging, computed tomography, MRI, and using different medical imaging modalities. This paper provides a systematic review of the literature on artificial neural network histopathology images [5-7]. Figure 1 shows an example of (ANN) based models for the diagnosis of breast cancer via breast mammography, while Figure 2 shows an example of mammography. The advantages and limitations of different screening of mammograms. Medical imaging is generally ANN models including spiking neural network (SNN), deep done by manually through one or other skilled doctors (such belief network (DBN), convolutional neural network (CNN), as sinologists, radiologists, or pathologists). The complete multilayer neural network (MLNN), stacked autoencoders decision is prepared after consent if several pathologists are (SAE), and stacked de-noising autoencoders (SDAE) are described in this review. The review also shows that the studies present for breast cancer histopathology image analysis; related to breast cancer detection applied different deep otherwise findings are described by a pathologist.
    [Show full text]
  • Current Status of Lymphography
    [CANCER RESEARCH 31, 1731-1732, November 1971] Current Status of Lymphography Manuel Viamonte, Jr. Departments of Radiology of the University of Miami School of Medicine, Miami, Florida 33146, the Mount Sinai Hospital, Miami Beach, Florida 33140, and the Jackson Memorial Hospital, Miami. Florida 33136 Summary nodes, and in patients with fungus disease, sarcoidosis, dermatopathic lymphopathy, rheumatoid arthritis, Lymphography is a simple, accurate, informative technique histiocytosis, and Waldenstrom macroglobulinemia. The with a minimum amount of complications and is of value in nonspecific lymph node enlargement without filling defects the assessment of patients with Hodgkin's disease. may be observed with specific and nonspecific adenitis. Small, punched out, filling defects can also be seen with the replacement of nodal parenchyma (such as by fibrosis), in The indications for foot lymphography in Hodgkin's disease incompletely filled nodes, and postirradiation. False-positive are (a) diagnosis of the disease clinically suspected but not examination may be seen in patients affected by concurrent or confirmed; (b) staging of confirmed and clinically localized previous processes involving lymph nodes, such as infectious Hodgkin's disease; and (c) its treatment. mononucleosis, and tuberculosis. In patients with lymphoma, lymphography may reveal involvement of supraclavicular Radiotherapy (usually left) or inguinal nodes which should guide the surgeon as to the site for biopsy. For the radiotherapist, the outline of involved nodes assists Stages I and II of the disease may prove to be extensive in determining the treatment areas. Follow-up studies of the (Stage III) after lymphography. The incidence of pelvis, abdomen, and chest permit an appraisal of response to retroperitoneal node involvement has been stated to be from 0 treatment and of possible recurrences (9).
    [Show full text]
  • Radiocolloid Lymphoscintigraphy in Neoplastic Disease1
    [CANCER RESEARCH 40, 3065-3071. August 1980] 0008-5472/80/0040-0000$02.00 Radiocolloid Lymphoscintigraphy in Neoplastic Disease1 GuneçN. Ege Department of Nuclear Medicine. The Princess Margaret Hospital, Toronto, Ontario M4X 7K9, Canada Abstract to the drainage lymph nodes, where the radiocolloid is lodged and a scintillation camera image providing functional, as well The transport and intralymphatic deposition of interstitially as anatomic and morphological data, is obtained (27). Because injected radiocolloid of suitable physical properties are medi lymphatic cannulation is not required, the technique is versatile ated through physiological processes and provide the means and is applicable to many more anatomic sites than is the for obtaining scintigraphic images of drainage lymph nodes lymphogram. relevant to the injection site. In a large series of patients with To date, interstitial lymphoscintigraphy has been most widely breast carcinoma, high correlation has been shown between used to study the internal mammary lymphatics in patients with the internal mammary lymphoscintigram and clinicopathologi- breast carcinoma with the objective of improving current stag cal stage of disease and prognosis. Since radiocolloid transport ing criteria (1, 7, 8, 9). The technique has also provided precise to, transit through, and deposition within the lymph node are lymph node localization for accurate parasternal radiation (4, effected through cellular elements concerned with immunolog- 6). More recently, interstitial radiocolloid lymphoscintigraphy ical mechanisms, it is proposed that the radiocolloid lympho has been utilized for visualizing pelvic lymphatics (10). scintigram be viewed not only as a technique for documenting morphologically established neoplasms in regional lymph Materials and Methods nodes but also as a modality for the recognition of functional changes which may influence the development of such neo Of the many agents used in radionuclide lymphoscintigraphy, plasms.
    [Show full text]
  • References Thorotrast Granuloma of Periaortic Nodes
    Thorotrast Granuloma of Periaortic Nodes 85 Lymphography is also useful in detecting completeness of lymphadenectomies doing operations simply by checking opacified nodes on an abdominal X·ray f.tlm in the operat· ing room. It is to be emphasized that the lymphatic drainage of the distal portion of the cloacogenic zone is to the superficial inguinal lymph nodes. These lymph nodes should be carefully examined in the lymphogram and they are to be included in the lymph node disection at operation, along with the pelvic nodes. Case 1 is an example demonstrating failure to include inguinal lymph nodes in lymphadenectomy and the patient returned with tumor in the inguinal lymph nodes and wide spread metastasis. False positive changes in the lymph nodes in this region are coihmon and the usual cautions also apply here when interpreting the inguinal lymph node metastases. References 1 Cullen, P.K., Jr., Pontius, E.E. and R.I. San. 4 Grodsky, L.: Cloacogenic Cancer of Anorectal ders: Qoacogenic Anorectal Carcinoma. Dis. Junction: report of seven cases. Dis. Colon Colon and Rectum 9 (1966) 1·12 and Rectum 6 (1963) 3744 2 Glockman, M.G., A.R. Margulis: Cloacogenic 5 Kyaw, M.M., T. Gallagher, J.O. Haines: Cloac~ Carcinoma. Amer. J. Roentgenol, Rad. Thera-­ genic Carcinoma of Anorectal Junction: Roent· PY and Nuclear Medicine. 107 (1969)175·180 genologic Diagnosis. Amer. J. Roentgenol, Rad. 3 Grinvalsky, H.T., E.B. Helwig: Carcinoma of Therapy and Nuclear Med. 115 (1972) 384·391 Anorectal Junction. I Histological Considera· 6 Mainer, J., C. Bowerman: Qoacogenic Carcin~ tions. Cander 1956, 480488 rna of Anorectal Junction.
    [Show full text]
  • Lymphography in Childhood: Six Years Experience with 242 Cases R.A
    74 R.A. Castellino et al. 10 Fro/and, S.S.: Binding of sheep erythrocytes to 17 Ross, G.D., E.M. Rabe/lino, M.J. Polley , H.H. human lymphocytes. A probable marker ofT Grey: Combined studies of complement receptor lymphocytes. Scand. J. Immunol. 1 (1972) 269 and surface immunoglobulin-bearing cells in 11 Fro/and, S.S., J. B. Natvig: Surface-bound im· normal and leukemic human lymphocytes. J. munoglobulin on lymphocytes from normal and clin. invest. 52 (1973) 3 77 immunodeficient humans. Scand. J. lmmunol. 1 18 Sipe, C.R., A.D. Clranana, E.P. Cronkite, D.D. (1972) 1 Joel, H. Schnappau[' The influence of varying dose 12 Greaves, M.F., J.J. T. Owen, M. Ra[[' T and B and repetitive short sessions of extracorporeal lymphocytes. Excerpta Medica Amsterdam/ irradiation of the blood on the production of American Publishing Co. Inc. New York (1973) lymphocytopenia. Rad. Research 25 (1965) 684 13 Heier, H.E.: The influence of mechanical force 19 Scjemsviird, J, M fonda/, F. Vanky, H. Wigzell, on the rosette test for human T. lymphocytes. R. Sealy: Lymphopenia and change in distribution Scand. J. lmmunol. 3 (1974) 677 of hu man T and B lymphocytes in peripheral blood 14 f onda/, M, G. Holm, H. Wigze/1: Surface markers induced by irradiation for mammary carcinoma. on human B and T lymphocytes. I. A large popu· Lancet 1 (1972) 1352 lation of lymphocytes forming non-immune 20 Storb, R., H. Ragde, E.D. Thomas: Extracorporeal rosettes with sheep red blood cells. J. Exp. Med. irradiation of the blood in baboons.
    [Show full text]